The implication of miRNA in the pathophysiology of ALS, in particular, in relation to the global RNA metabolism alterations that characterize the disease and the impairment of RNA-binding proteins (RBPs) such as FUS and TDP-43, and their potential as biomarkers and therapeutic targets have recently been reviewed elsewhere [21,22]. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.